Cat. No.: HY-10984

Pomalidomide

Name: Pomalidomide
Brand: MedChemExpress
SKU: HY-10984
Price: 42.00 USD
Availability: InStock
Rating: 5 (39 reviews)

(Synonyms: CC-4047; Actimid)

39 Cited Publications

Customer Review

Based on 39 publication(s) in Google Scholar

Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

For research use only. We do not sell to patients.

Purity : 99.88%
CAS No.: 19171-19-8
Formula: C₁₃H₁₁N₃O₄
Molecular Weight:273.24

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Pomalidomide Chemical Structure

CAS No.: 19171-19-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (39)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]^[2]^[3]^[4]

IL-1

TNF-alpha

IL-12

IL-2

IL-5

IL-10

IL-11

FOXP3

CDK2

OX-40

CDK4

CDK6

Cereblon

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

All FOXP Isoforms :

FOXP3

All Orexin Receptor (OX Receptor) Isoforms :

All CDK Isoforms :

All Ligands for E3 Ligase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
OPM-2	IC50	0.038 μM	Antiproliferative activity against human OPM-2 multiple myeloma cells assessed by [3H]-thymidine incorporation after 3-day culture. Antiproliferative activity against human OPM-2 multiple myeloma cells assessed by [3H]-thymidine incorporation after 3-day culture.	23203815
NCI-H929	IC50	0.035 μM	Antiproliferative activity against human H929 multiple myeloma cells assessed by [3H]-thymidine incorporation after 3-day culture. Antiproliferative activity against human H929 multiple myeloma cells assessed by [3H]-thymidine incorporation after 3-day culture.	23203815
U-266	IC50	0.028 μM	Antiproliferative activity against human U266 multiple myeloma cells assessed by [3H]-thymidine incorporation after 3-day culture. Antiproliferative activity against human U266 multiple myeloma cells assessed by [3H]-thymidine incorporation after 3-day culture.	23203815

In Vitro

Adaptive ImmunityCytokines and ChemokinesImmune Tolerance & ImmunosuppressionAnti-cancerCell Cycle RegulationApoptosisInnate ImmunityInflammasomeCytokines & ChemokinesOthers

Adaptive Immunity

Cytokines and Chemokines

Pomalidomide enhances IL-2 production in anti-CD3-stimulated primary human T cells with an EC₅₀ of 0.022 µM^[2].

Adaptive Immunity

Immune Tolerance & Immunosuppression

Pomalidomide (10 μM; 12 days) inhibits IL-2-driven expansion of human PBMC CD4+CD25high CTLA-4+FOXP3+ T regulatory cells, with an IC₅₀ of approximately 1 μM on day 7^[3].
Pomalidomide eliminates the suppressive function of human T regulatory cells on autologous CD4+CD25− responder cells^[3].
Pomalidomide (0.001-10 μM; 24 h) reduces FOXP3 expression in purified human T regulatory cells, with an inhibition rate of up to 50% at 10 μM^[3].
Pomalidomide (0.001-1 μM; 24 h) inhibits OX40 expression on purified human T regulatory cells at concentrations as low as 0.01 μM without affecting GITR^[3].

Anti-cancer

Pomalidomide inhibits the proliferation of OPM-2, H929, and U266 MM cells, with IC₅₀ values of 0.038, 0.035, and 0.028 µM, respectively^[2].

Anti-cancer

Cell Cycle Regulation

Pomalidomide (1 µM; 24 h) upregulates p21^WAF-1 and inhibits the proliferation of LP-1 and U266 cells, with G0-G1 phase arrest exceeding 59% after 3 days^[4].

Anti-cancer

Cell Cycle Regulation

Apoptosis

Pomalidomide (CC-4047) (0.001-10 µM; 72 h) arrests Namalwa cells in the G0-G1 phase and inhibits proliferation, with G0-G1 phase arrest reaching 79.5% at 10 µM^[4].

Apoptosis

Pomalidomide (0.001-10 µM; 3 days) in combination with 1 mM VPA (Valproic acid) (HY-10585) synergistically promotes apoptosis in Namalwa cells^[4].

Cell Cycle Regulation

Pomalidomide (0.01-10 µM; 8-72 h) upregulates p21^WAF-1 in Namalwa cells and increases p21^WAF-1-CDK2/CDK4/CDK6 complexes, reducing pRb phosphorylation at 10 µM^[4].
Pomalidomide (24 h)-induced G0-G1 phase arrest in Namalwa cells requires p21^WAF-1^[4].
Pomalidomide (0.001-100 µM; 6 days) expands CD34+ progenitor cells and increases p21^WAF-1 without inhibiting CDK2 activity^[4].

Cell Cycle Regulation

Apoptosis

Pomalidomide (0.1-1 µM; 24-72 h) protects normal B cells from apoptosis and, at 1 µM, does not induce p21^WAF-1 or alter pRb phosphorylation^[4].

Innate Immunity

Adaptive Immunity

Cytokines and Chemokines

Inflammasome

Pomalidomide (10 μM; 7 days) inhibits the proliferation of FOXP3+ T regulatory cells in human PBMCs as measured by CFSE assay^[3].

Innate Immunity

Cytokines & Chemokines

Pomalidomide inhibits TNF-α production in LPS-stimulated human PBMCs with an IC₅₀ of 0.0031 µM^[2].

Others

Pomalidomide is primarily converted to the 5-hydroxy metabolite (M17) via CYP1A2 and CYP3A4, with estimated contributions of 54% and 30%, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[4]

Cell Line:

Namalwa Burkitt’s lymphoma cells
Concentration:

0.1, 1, and 10 µM (cell cycle); 0.001, 0.01, 0.1, 1, and 10 µM (cell number/apoptosis); 0.01, 0.1, 1, and 10 µM (cell number, days 3, 4, and 5)
Incubation Time:

72 h (cell cycle); 72 h (cell number/apoptosis); days 3, 4, and 5 (cell number)
Result:

Increased G0-G1 phase cells to 53.1% at 0.1 µM, 72.3% at 1 µM, and 79.5% at 10 µM, with corresponding decreases in S-phase cells to 35.2%, 18.3%, and 15.3%.
Decreased Namalwa cell number dose-dependently without significantly affecting apoptosis.
Produced a 4-fold decrease in cell number at 10 µM by day 5.

Western Blot Analysis^[4]

Cell Line:

Namalwa cells
Concentration:

0.01, 0.1, 1, and 10 µM (p21^WAF-1 mRNA/protein); 0.01, 0.1, 1, and 10 µM (CDK immunoprecipitation and pRb phosphorylation)
Incubation Time:

8, 24, and 72 h (p21^WAF-1 mRNA/protein); 24 h (CDK immunoprecipitation and pRb phosphorylation)
Result:

Increased p21^WAF-1 mRNA and protein in a dose- and time-dependent manner.
Enhanced p21^WAF-1 binding to CDK2, CDK4, and CDK6 and decreased pRb phosphorylation at Ser795, Ser608, Ser780, Ser612, and Thr821 without changing total pRb protein.

Apoptosis Analysis^[4]

Cell Line:

Namalwa cells
Concentration:

0.001, 0.01, 0.1, 1, and 10 µM; VPA 0.1, 0.3, and 1 mM
Incubation Time:

3 days
Result:

At 0.1 mM, VPA was additive, whereas at 1 mM, VPA was synergistic in inducing Namalwa cell apoptosis.

In Vivo

Anti-cancerAdaptive ImmunityImmune Tolerance & Immunosuppression

Anti-cancer

Adaptive Immunity

Immune Tolerance & Immunosuppression

Pomalidomide (50 mg/kg; i.p.; daily; 6 days) reduces draining lymph node T regulatory cell expansion after CT26 tumor challenge without affecting conventional CD4⁺ populations or splenic T regulatory cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (female, approximately 12-15 weeks old)^[3]
Dosage:

50 mg/kg
Administration:

i.p.; daily; 6 days
Result:

In draining lymph nodes, CD4+CD25+CTLA-4+FOXP3+ T regulatory cells were reduced by 40% compared with the PBS control.
T regulatory cells averaged 11% of the CD4 population in non-tumor-challenged mice and increased to 18% after CT26 challenge; draining lymph node T regulatory cells were reduced to levels seen in non-tumor-challenged animals.
No significant reduction in T regulatory cells was seen in the spleen.
CD25−CD4+ cells or total CD4+ lymphocyte numbers in lymph nodes or spleen were not affected.

Related Protocols :

Chemical Information

CAS No. 19171-19-8
Appearance Solid
Molecular Weight 273.24
Formula C₁₃H₁₁N₃O₄
Color Light yellow to yellow
SMILES

O=C1N(C(C2=C1C=CC=C2N)=O)C(C(N3)=O)CCC3=O
Synonyms

CC-4047; Actimid
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (39)

All WB

Sort by:

Journal Impact Factor

Cancer Cell

High-performance multiplex drug-gated CAR circuits. [Abstract]

2022 Nov 14;40(11):1294-1305.e4. PMID: 36084652
Cell

Structural basis and regulation of the reductive stress response. [Abstract]

2021 Oct 14;184(21):5375-5390.e16. PMID: 34562363
Nat Cancer

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. [Abstract]

2022 May;3(5):595-613. PMID: 35534777

Pomalidomide purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 May;3(5):595-613. [Abstract]

Western blot analysis for IKAROS, CK1α and MENIN protein following treatment of MV4;11 human MLL-r AML cell line for 5 hours with increasing doses of Thalidomide, lenalidomide, Pomalidomide and iberdomide (10,100, 1000 nM), using ACTIN as a loading control.
Cancer Res

CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor Resistance. [Abstract]

2025 Oct 28. PMID: 41150906
Nat Commun

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability. [Abstract]

2024 Mar 16;15(1):2377. PMID: 38493213
Nat Commun

Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis. [Abstract]

2022 Sep 10;13(1):5324. PMID: 36088459

Pomalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Sep 10;13(1):5324. [Abstract]

Western immunoassays used to monitor changes in BNC2 levels in LX2 cells treated with 1 μM pomalidomide (Pom.), thalidomide (Thal.), CC-885, Iberdomide (Iber.) or vehicle for 24 h.
Nat Commun

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. [Abstract]

2017 May 22:8:15398. PMID: 28530236

Pomalidomide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2017 May 22:8:15398. [Abstract]

NUDT1 immunoblots using SF188 cells pretreated with pomalidomide (10 µM) for 2 h, and then subjected to an additional 6 h treatment with DMSO or LC-1-40 (50 nM).
Acta Pharm Sin B

2026 Feb 10.
Adv Sci (Weinh)

2026 Jul 17:e76662. PMID: 42467865
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 15;6(4):102053. PMID: 40187357
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Transl Med

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]

2024 Dec 3;22(1):1095. PMID: 39623468
Mol Ther Oncol

Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs. [Abstract]

2025 Feb 20;33(1):200952. PMID: 40123976
Cell Rep

2026 Jul 28;45(8):117762. PMID: 42519831
J Med Chem

Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. [Abstract]

2024 Oct 24;67(20):18247-18264. PMID: 39388374
Drug Des Devel Ther

2026 Jan 22;20:1-21.
Eur J Pharmacol

Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling. [Abstract]

2025 Dec 5:1008:178303. PMID: 41183585
Int Immunopharmacol

Pomalidomide promotes macrophage control of Mycobacterium tuberculosis via enhancing HDAC6-mediated autophagy. [Abstract]

2025 Jun 17:158:114831. PMID: 40373598
Cancers (Basel)

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma. [Abstract]

2024 Mar 28;16(7):1319. PMID: 38610997
Structure

CAND1 and CAND2 drive CUL4 substrate receptor exchange with largely comparable biochemical efficiency, unlike their relative effects on CUL1. [Abstract]

2026 Mar 20:S0969-2126(26)00056-0. PMID: 41864201
iScience

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells. [Abstract]

2023 Jun 7;26(7):107059. PMID: 37360684
Clin Exp Immunol

Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. [Abstract]

2021 Jul;205(1):53-62. PMID: 33735518
Gen Comp Endocrinol

Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.). [Abstract]

2016 Mar 1:228:1-8. PMID: 26747182

Pomalidomide purchased from MedChemExpress. Usage Cited in: Gen Comp Endocrinol. 2016 Mar 1:228:1-8. [Abstract]

TNFα significantly inhibits the mRNA and protein expression of GSK-3β, while POM significantly induces the mRNA and protein expression of GSK-3β (A). The mRNA and protein expression of β-catenin is significantly induced by TNFα, but significantly inhibited by POM (B). The protein expression of PPARγ and C/EBPα is significantly inhibited by TNFα, while significantly induced by POM treatment (C and D).
Stem Cells Dev

The Supportive Role of Lymph Node Mesenchymal Stromal Cells in Follicular Lymphoma Involves the PITX1-hTERT-Podoplanin Axis. [Abstract]

2025 Mar 25. PMID: 40130551
Biomed Pharmacother

2026 Sep:202:119803. PMID: 42537395
SSRN

2026 Jul 13.
bioRxiv

A bulk cell heterozygous knock-in strategy for targeted protein degradation. [Abstract]

2026 May 21:2026.05.19.726384. PMID: 42239119
bioRxiv

Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells. [Abstract]

2026 Feb 8:2026.02.06.704516. PMID: 41822826
Charles University

2026.
Chemrxiv

2025 Nov 17.
Harvard University

2025.
bioRxiv

2025 Jun 19.
bioRxiv

2025 January 08.
Patent

US20240245677A1.
University of Colorado Denver

2024.
University of Colorado Denver

2024.
bioRxiv

2024 Jan 28.
Elife

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. [Abstract]

2018 Aug 1:7:e38430. PMID: 30067223

Pomalidomide purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1:7:e38430. [Abstract]

H9 hESC are treated with increasing concentrations of Thalidomide, Lenalidomide, Pomalidomide, or DMSO as a control. Following 24 h of incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.
Masaryk University

2014.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (182.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6598 mL

18.2989 mL

36.5979 mL

5 mM

0.7320 mL

3.6598 mL

7.3196 mL

10 mM

0.3660 mL

1.8299 mL

3.6598 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.5% Tween-80 in Saline water

Solubility: 10 mg/mL (36.60 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (301 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tefferi A, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 20;27(27):4563-9.

[2]. Hoffmann M, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013 Feb;71(2):489-501. [Content Brief]

[3]. Galustian C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer immunology, immunotherapy : CII. 2009 Jul;58(7):1033-45.

[4]. Verhelle D, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer research. 2007 Jan 15;67(2):746-55.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6598 mL	18.2989 mL	36.5979 mL	91.4947 mL
	5 mM	0.7320 mL	3.6598 mL	7.3196 mL	18.2989 mL
	10 mM	0.3660 mL	1.8299 mL	3.6598 mL	9.1495 mL
	15 mM	0.2440 mL	1.2199 mL	2.4399 mL	6.0996 mL
	20 mM	0.1830 mL	0.9149 mL	1.8299 mL	4.5747 mL
	25 mM	0.1464 mL	0.7320 mL	1.4639 mL	3.6598 mL
	30 mM	0.1220 mL	0.6100 mL	1.2199 mL	3.0498 mL
	40 mM	0.0915 mL	0.4575 mL	0.9149 mL	2.2874 mL
	50 mM	0.0732 mL	0.3660 mL	0.7320 mL	1.8299 mL
	60 mM	0.0610 mL	0.3050 mL	0.6100 mL	1.5249 mL
	80 mM	0.0457 mL	0.2287 mL	0.4575 mL	1.1437 mL
	100 mM	0.0366 mL	0.1830 mL	0.3660 mL	0.9149 mL

Bioz

Pomalidomide

39 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Pomalidomide

Publications Citing Use of MedChemExpress (MCE) Pomalidomide

All TNF Receptor Isoforms

All Interleukin Related Isoforms

All FOXP Isoforms

All Orexin Receptor (OX Receptor) Isoforms

All CDK Isoforms

All Ligands for E3 Ligase Isoforms

Biological Activity

Description

IC₅₀ & Target

Cellular Effect

In Vitro

In Vivo

Chemical Information

Publications (39)

Solvent & Solubility

In Vitro:

In Vivo:

In Vivo Dissolution Calculator

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

Your Recently Viewed Products

Pomalidomide

Publications Citing Use of MedChemExpress (MCE) Pomalidomide

All TNF Receptor Isoforms

All Interleukin Related Isoforms

All FOXP Isoforms

All Orexin Receptor (OX Receptor) Isoforms

All CDK Isoforms

All Ligands for E3 Ligase Isoforms

Biological Activity

Description

IC50 & Target

Cellular Effect

In Vitro

In Vivo

Chemical Information

Publications (39)

Solvent & Solubility

In Vitro:

In Vivo:

In Vivo Dissolution Calculator

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Pomalidomide Related Classifications

HY-10984 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target